Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial
Stephen A. Harrison, Will Fecht, Elizabeth M. Brunt, Brent A. Neuschwander‐Tetri – 28 December 2008 – The aim of this study was to determine if orlistat, an inhibitor of fat absorption, combined with caloric restriction in overweight subjects with nonalcoholic steatohepatitis results in weight loss and improved liver histology. Fifty overweight subjects (body mass index = ≥27) with biopsy proven nonalcoholic steatohepatitis were randomized to receive a 1,400 Kcal/day diet plus vitamin E (800 IU) daily with or without orlistat (120 mg three times a day) for 36 weeks.